Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 22-29

  Watson, Sheree ^a   Pensabene, Licia ^b   Mitchell, Paul ^a   Bousvaros, Athos ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

pediatrics; side effects of medications; tacrolimus; ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METRONIDAZOLE; PREDNISONE; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CANDIDEMIA; CHILD; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; DEATH; DISEASE ACTIVITY; DRUG DOSE TITRATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; HEADACHE; HOSPITAL DISCHARGE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LENGTH OF STAY; MALE; MEDICAL RECORD REVIEW; NEPHROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SEIZURE; SIDE EFFECT; THRUSH; TREATMENT OUTCOME; TREMOR; ULCERATIVE COLITIS; VAGINITIS;

EID: 78650109092     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21418     Document Type: Article

References (44)

1. Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut. 2008; 57: 331-338.
2. Werlin SL, Grand RJ,. Severe colitis in children and adolescents: diagnosis, course, and treatment. Gastroenterology. 1977; 73 (4 Pt 1): 828-832.
3. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330: 1841-1845.
4. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006; 55: 1255-1262.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476. (Pubitemid 41770166)
6. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003; 125: 380-388.
7. Goto T, Kino T, Hatanaka H, et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc. 1987; 19 (5 Suppl 6): 4-8. (Pubitemid 17157071)
8. Siekierka JJ, Sigal NH,. FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. Curr Opin Immunol. 1992; 4: 548-552.
9. Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis. 2009; 53: 760-769.
10. Kondo H, Abe T, Hashimoto H, et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J Rheumatol. 2004; 31: 243-251.
11. Stephens J, Goldstein R, Crippin J, et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. Transplant Proc. 1993; 25 (1 Pt 2): 1122-1123.
12. Talwalkar JA, Gossard AA, Keach JC, et al. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int. 2007; 27: 451-453.
13. Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008; 28: 589-597.
14. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749-753.
15. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (suppl A): 5-36.
16. Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr. 2000; 137: 794-799.
17. Bousvaros A, Wang A, Leichtner AM,. Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr. 1996; 23: 329-333.
18. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007; 133: 423-432.
19. Benson A, Barrett T, Sparberg M, et al. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis. 2008; 14: 7-12.
20. Ng SC, Arebi N, Kamm MA,. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 129-134.
21. Ziring DA, Wu SS, Mow WS, et al. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr. 2007; 45: 306-311.
22. Eidelwein AP, Cuffari C, Abadom V, et al. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis. 2005; 11: 213-218.
23. Fanjiang G, Russell GH, Katz AJ,. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2007; 44: 312-317.
24. Mamula P, Markowitz JE, Brown KA, et al. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2002; 34: 307-311.
25. Mamula P, Markowitz JE, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr. 2004; 38: 298-301.
26. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010; 138: 2282-2291.
27. Cohen RD, Stein R, Hanauer SB,. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999; 94: 1587-1592.
28. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs. 1993; 46: 746-794.
29. Rufo PA, Bousvaros A,. Current therapy of inflammatory bowel disease in children. Paediatr Drugs. 2006; 8: 279-302. (Pubitemid 44607534)
30. Starzl TE,. FK 506 versus cyclosporine. Transplant Proc. 1993; 25 (1 Pt 1): 511-512.
31. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007; 13: 1024-1030.
32. Kwon JH, Farrell RJ,. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol. 2005; 56: 169-178.
33. Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol. 2006; 101: 1048-1056.
34. Baumgart DC, Wiedenmann B, Dignass AU,. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 17: 1273-1281.
35. Fellermann K, Herrlinger KR, Witthoeft T, et al. Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease. Transplant Proc. 2001; 33: 2247-2248.
36. Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol. 1998; 93: 1860-1866.
37. Hogenauer C, Wenzl HH, Hinterleitner TA, et al. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther. 2003; 18: 415-423.
38. Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2008; 6: 1112-1116.
39. Cacheux W, Seksik P, Lemann M, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2008; 103: 637-642.
40. Hait EJ, Bousvaros A, Schuman M, et al. Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. J Pediatr Surg. 2007; 42: 31-34; discussion 4-5.
41. Castro M, Papadatou B, Ceriati E, et al. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langenbecks Arch Surg. 2007; 392: 161-164.
42. Barabino A, Torrente F, Castellano E, et al. The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience. Aliment Pharmacol Ther. 2002; 16: 1503-1507. (Pubitemid 34953591)
43. Treem WR, Cohen J, Davis PM, et al. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum. 1995; 38: 474-479.
44. Treem WR, Davis PM, Hyams JS,. Cyclosporine treatment of severe ulcerative colitis in children. J Pediatr. 1991; 119: 994-997.